Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Orphanet Journal of Rare Diseases
Published in: Orphanet Journal of Rare Diseases 1/2024

Open Access 01-12-2024 | Congenital Adrenal Hyperplasia | Research

Genetic diagnosis of endocrine disorders in Cyprus through the Cyprus Institute of Neurology and Genetics: an ENDO-ERN Reference Center

Authors: Vassos Neocleous, Pavlos Fanis, Meropi Toumba, Nicos Skordis, Leonidas A. Phylactou

Published in: Orphanet Journal of Rare Diseases | Issue 1/2024

Login to get access

Abstract

The report covers the current and past activities of the department Molecular Genetics-Function and Therapy (MGFT) at the Cyprus Institute of Neurology and Genetics (CING), an affiliated Reference Center for the European Reference Network on Rare Endocrine Conditions (Endo-ERN).
The presented data is the outcome of > 15 years long standing collaboration between MGFT and endocrine specialists from the local government hospitals and the private sector. Up-to-date > 2000 genetic tests have been performed for the diagnosis of inherited rare endocrine disorders. The major clinical entities included Congenital Adrenal Hyperplasia (CAH) due to pathogenic variants in CYP21A2 gene and Multiple Endocrine Neoplasia (MEN) type 2 due to pathogenic variants in the RET proto-oncogene. Other rare and novel pathogenic variants in ANOS1, WDR11, FGFR1, RNF216, and CHD7 genes were also found in patients with Congenital Hypogonadotropic Hypogonadism. Interestingly, a few patients with Disorders of Sexual Differentiation (DSD) shared rare pathogenic variants in the SRD5A2, HSD17B3 and HSD3B2 while patients with Glucose and Insulin Homeostasis carried theirs in GCK and HNF1A genes. Lastly, MGFT over the last few years has established an esteemed diagnostic and research program on premature puberty with emphasis on the implication of MKRN3 gene on the onset of the disease and the identification of other prognosis biomarkers.
As an Endo-ERN member MGFT department belongs to this large European network and holds the same humanistic ideals which aim toward the improvements of health care for patients with rare endocrine conditions in respect to improved and faster diagnosis.
Literature
1.
Eggermann T, Elbracht M, Kurth I, Juul A, Johannsen TH, Netchine I, Mastorakos G, Johannsson G, Musholt TJ, Zenker M, et al. Genetic testing in inherited endocrine disorders: joint position paper of the European reference network on rare endocrine conditions (Endo-ERN). Orphanet J Rare Dis. 2020;15(1):144.PubMedPubMedCentralCrossRef
2.
Phedonos AA, Shammas C, Skordis N, Kyriakides TC, Neocleous V, Phylactou LA. High carrier frequency of 21-hydroxylase deficiency in Cyprus. Clin Genet. 2013;84(6):585–8.PubMedCrossRef
3.
Neocleous V, Fanis P, Toumba M, Stylianou C, Picolos M, Andreou E, Kyriakou A, Iasonides M, Nicolaou S, Kyriakides TC, et al. The spectrum of genetic defects in congenital adrenal hyperplasia in the population of cyprus: a retrospective analysis. Horm Metab Res. 2019;51(9):586–94.PubMedCrossRef
4.
Fanis P, Skordis N, Toumba M, Papaioannou N, Makris A, Kyriakou A, Neocleous V, Phylactou LA. Central precocious puberty caused by novel mutations in the promoter and 5’-UTR region of the imprinted MKRN3 gene. Front Endocrinol. 2019;10:677.CrossRef
5.
Fanis P, Morrou M, Tomazou M, Michailidou K, Spyrou GM, Toumba M, Skordis N, Neocleous V, Phylactou LA. Methylation status of hypothalamic Mkrn3 promoter across puberty. Front Endocrinol. 2022;13:1075341.CrossRef
6.
Skordis N, Shammas C, Efstathiou E, Sertedaki A, Neocleous V, Phylactou L. Late diagnosis of 5alpha steroid-reductase deficiency due to IVS12A>G mutation of the SRD5a2 gene in an adolescent girl presented with primary amenorrhea. Hormones (Athens). 2011;10(3):230–5.PubMedCrossRef
7.
Neocleous V, Sismani C, Shammas C, Efstathiou E, Alexandrou A, Ioannides M, Argyrou M, Patsalis PC, Phylactou LA, Skordis N. Duplication of exons 3–10 of the HSD17B3 gene: a novel type of genetic defect underlying 17beta-HSD-3 deficiency. Gene. 2012;499(2):250–5.PubMedCrossRef
8.
Galli-Tsinopoulou A, Serbis A, Kotanidou EP, Litou E, Dokousli V, Mouzaki K, Fanis P, Neocleous V, Skordis N. 46, XY disorder of sex development due to 17-beta hydroxysteroid dehydrogenase type 3 deficiency in an infant of Greek origin. J Clin Res Pediatr Endocrinol. 2018;10(1):74–8.PubMedCrossRef
9.
Neocleous V, Fanis P, Cinarli F, Kokotsis V, Oulas A, Toumba M, Spyrou GM, Phylactou LA, Skordis N. 46, XY complete gonadal dysgenesis in a familial case with a rare mutation in the desert hedgehog (DHH) gene. Hormones (Athens). 2019;18(3):315–20.PubMedCrossRef
10.
Fanis P, Neocleous V, Kosta K, Karipiadou A, Hartmann MF, Wudy SA, Karantaglis N, Papadimitriou DT, Skordis N, Tsikopoulos G, et al. Late diagnosis of 3beta-Hydroxysteroid dehydrogenase deficiency: the pivotal role of gas chromatography-mass spectrometry urinary steroid metabolome analysis and a novel homozygous nonsense mutation in the HSD3B2 gene. J Pediatr Endocrinol Metab. 2021;34(1):131–6.PubMedCrossRef
11.
Fanis P, Skordis N, Frangos S, Christopoulos G, Spanou-Aristidou E, Andreou E, Manoli P, Mavrommatis M, Nicolaou S, Kleanthous M, et al. Multiple endocrine neoplasia 2 in Cyprus: evidence for a founder effect. J Endocrinol Invest. 2018;41(10):1149–57.PubMedPubMedCentralCrossRef
12.
Neocleous V, Fanis P, Toumba M, Tanteles GA, Schiza M, Cinarli F, Nicolaides NC, Oulas A, Spyrou GM, Mantzoros CS, et al. GnRH deficient patients with congenital hypogonadotropic hypogonadism: novel genetic findings in ANOS1, RNF216, WDR11, FGFR1, CHD7, and POLR3A genes in a case series and review of the literature. Front Endocrinol. 2020;11:626.CrossRef
13.
Fanis P, Neocleous V, Papapetrou I, Phylactou LA, Skordis N. Gonadotropin-Releasing Hormone Receptor (GnRHR) and hypogonadotropic hypogonadism. Int J Mol Sci. 2023;24(21):15965.PubMedPubMedCentralCrossRef
14.
Neocleous V, Shammas C, Phelan MM, Nicolaou S, Phylactou LA, Skordis N. In silico analysis of a novel MKRN3 missense mutation in familial central precocious puberty. Clin Endocrinol (Oxf). 2016;84(1):80–4.PubMedCrossRef
15.
Skordis N, Ferrari E, Antoniadou A, Phylactou LA, Fanis P, Neocleous V. GnRH-dependent precocious puberty manifested at the age of 14 months in a girl with 47, XXX karyotype. Hormones (Athens). 2017;16(3):318–21.PubMed
16.
Christoforidis A, Skordis N, Fanis P, Dimitriadou M, Sevastidou M, Phelan MM, Neocleous V, Phylactou LA. A novel MKRN3 nonsense mutation causing familial central precocious puberty. Endocrine. 2017;56(2):446–9.PubMedCrossRef
17.
Neocleous V, Fanis P, Toumba M, Gorka B, Kousiappa I, Tanteles GA, Iasonides M, Nicolaides NC, Christou YP, Michailidou K, et al. Pathogenic and low-frequency variants in children with central precocious puberty. Front Endocrinol. 2021;12:745048.CrossRef
18.
Shammas C, Neocleous V, Phelan MM, Lian LY, Skordis N, Phylactou LA. A report of 2 new cases of MODY2 and review of the literature: implications in the search for type 2 diabetes drugs. Metabolism. 2013;62(11):1535–42.PubMedCrossRef
19.
Toumba M, Fanis P, Vlachakis D, Neocleous V, Phylactou LA, Skordis N, Mantzoros CS, Pantelidou M. Molecular modelling of novel ADCY3 variant predicts a molecular target for tackling obesity. Int J Mol Med. 2022;49(1):10.PubMedCrossRef
20.
Neocleous V, Shammas C, Phelan MM, Fanis P, Pantelidou M, Skordis N, Mantzoros C, Phylactou LA, Toumba M. A novel MC4R deletion coexisting with FTO and MC1R gene variants, causes severe early onset obesity. Hormones (Athens). 2016;15(3):445–52.PubMed
21.
Merke DP, Auchus RJ. Congenital adrenal hyperplasia due to 21-hydroxylase deficiency. N Engl J Med. 2020;383(13):1248–61.PubMedCrossRef
22.
Auer MK, Nordenstrom A, Lajic S, Reisch N. Congenital adrenal hyperplasia. Lancet. 2023;401(10372):227–44.PubMedCrossRef
23.
New MI, Abraham M, Gonzalez B, Dumic M, Razzaghy-Azar M, Chitayat D, Sun L, Zaidi M, Wilson RC, Yuen T. Genotype-phenotype correlation in 1,507 families with congenital adrenal hyperplasia owing to 21-hydroxylase deficiency. Proc Natl Acad Sci U S A. 2013;110(7):2611–6.PubMedPubMedCentralCrossRef
24.
Silva RS, Carvalho B, Pedro J, Castro-Correia C, Carvalho D, Carvalho F, Fontoura M. Differences in hormonal levels between heterozygous CYP21A2 pathogenic variant carriers, non-carriers, and females with non-classic congenital hyperplasia. Arch Endocrin Metab. 2022;66(2):168–75.CrossRef
25.
Neocleous V, Shammas C, Phedonos AA, Phylactou LA, Skordis N. Phenotypic variability of hyperandrogenemia in females heterozygous for CYP21A2 mutations. Indian J Endocrinol Metab. 2014;18(Suppl 1):S72-79.PubMedPubMedCentral
26.
Neocleous V, Fanis P, Toumba M, Phedonos AAP, Picolos M, Andreou E, Kyriakides TC, Tanteles GA, Shammas C, Phylactou LA, et al. Variations in the 3’UTR of the CYP21A2 Gene in Heterozygous Females with Hyperandrogenaemia. Int J Endocrinol. 2017;2017:8984365.PubMedPubMedCentralCrossRef
27.
Guarnotta V, Niceta M, Bono M, Marchese S, Fabiano C, Indelicato S, Di Gaudio F, Garofalo P, Giordano C. Clinical and hormonal characteristics in heterozygote carriers of congenital adrenal hyperplasia. J Steroid Biochem Mol Biol. 2020;198:105554.PubMedCrossRef
28.
Neocleous V, Ioannou YS, Bartsota M, Costi C, Skordis N, Phylactou LA. Rare mutations in the CYP21A2 gene detected in congenital adrenal hyperplasia. Clin Biochem. 2009;42(13–14):1363–7.PubMedCrossRef
29.
Skordis N, Kyriakou A, Tardy V, Ioannou YS, Varvaresou A, Dracopoulou-Vabouli M, Patsalis PC, Shammas C, Neocleous V, Phylactou LA. Molecular defects of the CYP21A2 gene in Greek-Cypriot patients with congenital adrenal hyperplasia. Horm Res Paediatr. 2011;75(3):180–6.PubMedCrossRef
30.
Skordis N, Shammas C, Efstathiou E, Kaffe K, Neocleous V, Phylactou LA. Endocrine profile and phenotype-genotype correlation in unrelated patients with non-classical congenital adrenal hyperplasia. Clin Biochem. 2011;44(12):959–63.PubMedCrossRef
31.
Neocleous V, Shammas C, Phedonos AP, Karaoli E, Kyriakou A, Toumba M, Phylactou LA, Skordis N. Genetic defects in the cyp21a2 gene in heterozygous girls with premature adrenarche and adolescent females with hyperandrogenemia. Georgian Med News. 2012;210:40–7.
32.
Skordis N, Shammas C, Phedonos AA, Kyriakou A, Toumba M, Neocleous V, Phylactou LA. Genetic defects of the CYP21A2 gene in girls with premature adrenarche. J Endocrinol Invest. 2015;38(5):535–9.PubMedCrossRef
33.
Shammas C, Byrou S, Phelan MM, Toumba M, Stylianou C, Skordis N, Neocleous V, Phylactou LA. Genetic screening of non-classic CAH females with hyperandrogenemia identifies a novel CYP11B1 gene mutation. Hormones (Athens). 2016;15(2):235–42.PubMed
34.
Neocleous V, Fanis P, Phylactou LA, Skordis N. Genotype is associated to the degree of virilization in patients with classic congenital adrenal hyperplasia. Front Endocrinol. 2018;9:733.CrossRef
35.
Nowotny H, Neumann U, Tardy-Guidollet V, Ahmed SF, Baronio F, Battelino T, Bertherat J, Blankenstein O, Bonomi M, Bouvattier C, et al. Prenatal dexamethasone treatment for classic 21-hydroxylase deficiency in Europe. Eur J Endocrinol. 2022;186(5):K17–24.PubMedPubMedCentralCrossRef
36.
Johannsen TH, Albrethsen J, Neocleous V, Baronio F, Cools M, Aksglaede L, Jorgensen N, Christiansen P, Toumba M, Fanis P, et al. Reduced serum concentrations of biomarkers reflecting Leydig and Sertoli cell function in male patients with congenital adrenal hyperplasia. Endocr Connect. 2023;12(8):e230073.PubMedPubMedCentralCrossRef
37.
Fanis P, Skordis N, Phylactou LA, Neocleous V. Salt-wasting congenital adrenal hyperplasia phenotype as a result of the TNXA/TNXB chimera 1 (CAH-X CH-1) and the pathogenic IVS2-13A/C > G in CYP21A2 gene. Hormones (Athens). 2023;22(1):71–7.PubMedCrossRef
38.
Fanis P, Skordis N, Toumba M, Picolos M, Tanteles GA, Neocleous V, Phylactou LA. The pathogenic p.Gln319Ter variant is not causing congenital adrenal hyperplasia when inherited in one of the duplicated CYP21A2 genes. Front Endocrinol. 2023;14:1156616.CrossRef
39.
Baumgartner-Parzer S, Witsch-Baumgartner M, Hoeppner W. EMQN best practice guidelines for molecular genetic testing and reporting of 21-hydroxylase deficiency. Eur J Hum Genet. 2020;28(10):1341–67.PubMedPubMedCentralCrossRef
40.
Romei C, Mariotti S, Fugazzola L, Taccaliti A, Pacini F, Opocher G, Mian C, Castellano M, degli Uberti E, Ceccherini I, et al. Multiple endocrine neoplasia type 2 syndromes (MEN 2): results from the ItaMEN network analysis on the prevalence of different genotypes and phenotypes. Eur J Endocrinol. 2010;163(2):301–8.PubMedCrossRef
41.
Wells SA Jr, Asa SL, Dralle H, Elisei R, Evans DB, Gagel RF, Lee N, Machens A, Moley JF, Pacini F, et al. Revised American Thyroid Association guidelines for the management of medullary thyroid carcinoma. Thyroid. 2015;25(6):567–610.PubMedPubMedCentralCrossRef
42.
Eng C, Clayton D, Schuffenecker I, Lenoir G, Cote G, Gagel RF, van Amstel HK, Lips CJ, Nishisho I, Takai SI, et al. The relationship between specific RET proto-oncogene mutations and disease phenotype in multiple endocrine neoplasia type 2. International RET mutation consortium analysis. JAMA. 1996;276(19):1575–9.PubMedCrossRef
43.
American Thyroid Association Guidelines Task F, Kloos RT, Eng C, Evans DB, Francis GL, Gagel RF, Gharib H, Moley JF, Pacini F, Ringel MD, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid. 2009;19(6):565–612.CrossRef
44.
Elisei R, Alevizaki M, Conte-Devolx B, Frank-Raue K, Leite V, Williams GR. 2012 European thyroid association guidelines for genetic testing and its clinical consequences in medullary thyroid cancer. Eur Thyroid J. 2013;1(4):216–31.PubMedCrossRef
45.
Neocleous V, Passalaris T, Spanou E, Kitsios P, Skordis N, Deltas CC. Description of the first two seemingly unrelated Greek Cypriot families with a common C618R RET proto-oncogene mutation. Genet Test. 2004;8(2):163–8.PubMedCrossRef
46.
Neocleous V, Skordis N, Portides G, Efstathiou E, Costi C, Ioannou N, Pantzaris M, Anastasiadou V, Deltas C, Phylactou LA. RET proto-oncogene mutations are restricted to codon 618 in Cypriot families with multiple endocrine neoplasia 2. J Endocrinol Invest. 2011;34(10):764–9.PubMed
47.
Neocleous V, Fanis P, Frangos S, Skordis N, Phylactou LA. RET proto-oncogene variants in patients with medullary thyroid carcinoma from the Mediterranean basin: a brief report. Life (Basel). 2023;13(6):1332.PubMed
48.
Howard SR, Guasti L, Ruiz-Babot G, Mancini A, David A, Storr HL, Metherell LA, Sternberg MJ, Cabrera CP, Warren HR, et al. IGSF10 mutations dysregulate gonadotropin-releasing hormone neuronal migration resulting in delayed puberty. EMBO Mol Med. 2016;8(6):626–42.PubMedPubMedCentralCrossRef
49.
Kotan LD, Cooper C, Darcan S, Carr IM, Ozen S, Yan Y, Hamedani MK, Gurbuz F, Mengen E, Turan I, et al. Idiopathic Hypogonadotropic Hypogonadism Caused by Inactivating Mutations in SRA1. J Clin Res Pediatr Endocrinol. 2016;8(2):125–34.PubMedPubMedCentralCrossRef
50.
Dode C, Hardelin JP. Kallmann syndrome. European journal of human genetics : EJHG. 2009;17(2):139–46.PubMedCrossRef
51.
Skordis N, Neocleous V, Kyriakou A, Efstathiou E, Sertedaki A, Philibert P, Phylactou LA, Lumbroso S, Sultan C. The IVS1-2A>G mutation in the SRD5A2 gene predominates in Cypriot patients with 5alpha reductase deficiency. J Endocrinol Invest. 2010;33(11):810–4.PubMedCrossRef
52.
Kotan LD, Isik E, Turan I, Mengen E, Akkus G, Tastan M, Gurbuz F, Yuksel B, Topaloglu AK. Prevalence and associated phenotypes of PLXNA1 variants in normosmic and anosmic idiopathic hypogonadotropic hypogonadism. Clin Genet. 2019;95(2):320–4.PubMedCrossRef
Metadata
Title
Genetic diagnosis of endocrine disorders in Cyprus through the Cyprus Institute of Neurology and Genetics: an ENDO-ERN Reference Center
Authors
Vassos Neocleous
Pavlos Fanis
Meropi Toumba
Nicos Skordis
Leonidas A. Phylactou
Publication date
01-12-2024
Publisher
BioMed Central
Published in
Orphanet Journal of Rare Diseases / Issue 1/2024
Electronic ISSN: 1750-1172
DOI
https://doi.org/10.1186/s13023-024-03171-4

Other articles of this Issue 1/2024

Orphanet Journal of Rare Diseases 1/2024 Go to the issue

Research

‘BLUES’ procedure for assessing the blue level of the sclera in Osteogenesis Imperfecta

Research

Prevalence of Leber hereditary optic neuropathy in the Community of Madrid (Spain), estimation with a capture-recapture method

Research

The IMPACT Survey: the economic impact of osteogenesis imperfecta in adults

Research

Effectiveness of asfotase alfa for treatment of adults with hypophosphatasia: results from a global registry

Research

A newborn Screening Programme for Inborn errors of metabolism in Galicia: 22 years of evaluation and follow-up

Research

Clinical investigator perspectives on patient outcomes in children with neuronopathic mucopolysaccharidosis II during intrathecal idursulfase-IT treatment